VCYT Veracyte Inc
Company Analysis
Latest News
🔴 Veracyte is trading 57% down after narrowing its 2026 revenue outlook
Veracyte is trading 56.57% down at $22.20 after its November 4 earnings report raised concerns about slower growth. - Third-quarter revenue and adjusted...
🔴 Veracyte is trading 26.1% down in pre-market after lowering testing revenue guidance
Veracyte is trading at $38.80, down 26.12% in pre-market as its earnings outlook appears to be the main catalyst. - Q3 revenue was $151.8 million, up 15% year...
Veracyte Beat Wall Street's Numbers — So Why Did Investors Erase $700 Million in Market Value Overnight?
Shares of Veracyte cratered 17.2% to $43.50 after the cancer diagnostics company reported Q3 results on November 4 that, on paper, looked solid — but came...
🔴 Veracyte is trading 17.17% down in after-hours trading after narrowing FY2026 revenue outlook
Following the November 4 regular-session close, Veracyte is trading at $43.50, down 17.17%, after management narrowed the upper end of its FY2026 revenue...
Veracyte beats third quarter 2026 estimates and launches $100M repurchase for FY 2026
Veracyte delivered a significant top-line beat in the third quarter of 2026, with total revenue growing 15% year-over-year. While the company surpassed analyst...
🟢 Veracyte rises 4.3% — Biotech Sector Surges on Reduced Regulatory Concerns Post-Midterm Elections
With Biotech (XBI) up 2.0%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, proxied by the XBI ETF,...
🟢 Veracyte rises 4.1% — Biotech Stocks Rally on Sector Rotation as Tech Declines
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a significant rally,...
Veracyte Inc Q3 2026 Earnings Preview: What Analysts Expect on November 04, 2026
Veracyte is expected to post Q3 2026 consensus revenue of $124.82 million and EPS of $0.28, with the current $36.42 share price trading roughly 14% below the...
🟢 Veracyte rises 4.0% — Biotech Sector Rallies on Positive Clinical Trial Data and Regulatory News
With Biotech (XBI) up 2.2%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is trading higher today, driven by a...
🟢 Veracyte is trading 4.32% up in pre-market, with Decipher findings in focus
Veracyte is trading at $50.00, up 4.32% in pre-market on October 26; Decipher data is a plausible company-specific catalyst, though a direct link to the move...
🟢 Veracyte rises 4.0% — Biotech Sector Rallies on Positive Clinical Data and Regulatory News
With Biotech (XBI) up 2.2%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...
🔴 Veracyte is trading 4.1% down with no clear catalyst
Veracyte is trading 4.1% down at $43.38 on October 12, 2026, with no clear company-specific announcement explaining the intraday drop. - Recent coverage...
🟢 Veracyte rises 4.7% — Biotech Sector Rallies on Strong IPO Debuts and M&A Activity
With Biotech (XBI) up 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a significant rally,...
🔴 Veracyte is trading 4.21% down with no confirmed company catalyst
Veracyte is trading $41.34, down 4.21%, as the softer market backdrop may be weighing on shares. - No confirmed Veracyte-specific announcement or catalyst for...
🔴 Veracyte is trading 4.46% down today amid broader market and biotech weakness
Veracyte is trading 4.46% down at $42.66, with no confirmed company-specific announcement identified to explain the October 7, 2026 decline. - Broader...
🔴 Veracyte is trading 5% down today
Veracyte is trading 4.89% lower at $45.34 on October 6, 2026, with no confirmed company announcement directly explaining the decline. - Recent coverage points...
🟢 Veracyte is trading 4.1% up today amid broader gains; direct catalyst unconfirmed
Veracyte is trading at $47.67, up 4.06%, with broader market strength the likeliest context; a direct catalyst remains unconfirmed. - No verified...
🟢 Veracyte is trading 4.03% up on October 2, 2026, amid market rebound after weaker-than-expected payrolls
Veracyte is trading at $45.97, up +4.03%, likely reflecting a broader market rebound after weaker-than-expected September payrolls eased rate-hike concerns. -...
🟢 Veracyte is trading 5% up in after-hours trading with no clear catalyst
Veracyte is trading 4.89% higher at $46.35 after-hours, with no clear catalyst identified for the rebound. - The stock closed at $44.19 on October 1, 2026,...
🔴 Veracyte is trading 4% down — catalyst remains unclear
Veracyte is trading 4.02% down at $44.19, with no clear company-specific catalyst identified for the October 1, 2026 decline. - Recent company news included...